231 related articles for article (PubMed ID: 14598945)
21. New approaches to treatment of metastatic bladder cancer.
Edelman MJ
Curr Oncol Rep; 2000 Sep; 2(5):379-85. PubMed ID: 11122868
[TBL] [Abstract][Full Text] [Related]
22. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
23. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
VĂ©nat-Bouvet L; Ly K; Szelag JC; Martin J; Labourey JL; Genet D; Tubiana-Mathieu N
Anticancer Drugs; 2003 Nov; 14(10):829-32. PubMed ID: 14597878
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
Vogelzang NJ; Stadler WM
Urology; 1999 Feb; 53(2):243-50. PubMed ID: 9933034
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.
Protzel C; Zimmermann U; Asse E; Kallwellis G; Klebingat KJ
J Neurooncol; 2002 Apr; 57(2):141-5. PubMed ID: 12125975
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine in bladder cancer.
Sternberg CN
Semin Oncol; 2000 Feb; 27(1 Suppl 2):31-9. PubMed ID: 10697034
[TBL] [Abstract][Full Text] [Related]
28. What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine.
Simpson A
N Z Med J; 2005 Nov; 118(1225):U1733. PubMed ID: 16286946
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Abi-Aad AS
Acta Urol Belg; 1996 May; 64(2):43-5. PubMed ID: 8701810
[No Abstract] [Full Text] [Related]
30. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
[TBL] [Abstract][Full Text] [Related]
32. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
34. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero P; Marini L; Frea B
BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
[No Abstract] [Full Text] [Related]
35. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
[TBL] [Abstract][Full Text] [Related]
36. [Cerebral vasculitis associated with gemcitabine].
Schmorl P; Heer-Sonderhoff A; Vosshenrich R; Conrad S
Urologe A; 2010 Feb; 49(2):268-70. PubMed ID: 20213928
[TBL] [Abstract][Full Text] [Related]
37. Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Gschwend JE
Eur Urol; 2007 Aug; 52(2):486-7. PubMed ID: 17383081
[No Abstract] [Full Text] [Related]
38. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Marconato L; Zini E; Lindner D; Suslak-Brown L; Nelson V; Jeglum AK
J Am Vet Med Assoc; 2011 Apr; 238(8):1004-10. PubMed ID: 21492043
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Cohen MH; Rothmann M
J Clin Oncol; 2001 Feb; 19(4):1229-31. PubMed ID: 11181690
[No Abstract] [Full Text] [Related]
40. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
Brinkley WM; Torti FM
Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]